U.S. FDA panel backs Pfizer’s low-dose COVID-19 vaccine for children
The Hindu
A Food and Drug Administration advisory panel voted unanimously, that the vaccine’s benefits in preventing COVID-19 in the 5-11 age group outweigh any potential risks.
The U.S. moved a step closer to expanding COVID-19 vaccinations for millions more children as a panel of government advisers on Tuesday, October 26, 2021, endorsed kid-size doses offor .
A Food and Drug Administration advisory panel voted unanimously, with one abstention, that the vaccine’s benefits in preventing COVID-19 in that age group outweigh any potential risks — including a heart-related side effect that's been very rare in teens and young adults despite their use of a much higher shot dose.
Also read:
More Related News